Markets Maxim starts Unicycive Therapeutics at buy; PT $3 Maxim Group initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a “buy” rating and price target of $3. The stock closed at $1.07 on March 15. Unicycive is aiming to bring two key assets through clinical... March 16, 2022